Gerbasi, Margaret E.
Eldar-Lissai, Adi
Acaster, Sarah
Fridman, Moshe
Bonthapally, Vijayveer
Hodgkins, Paul
Kanes, Stephen J.
Meltzer-Brody, Samantha
Funding for this research was provided by:
Sage Therapeutics
Article History
Received: 10 February 2020
Accepted: 26 May 2020
First Online: 14 July 2020
Compliance with ethical standards
:
: The funding source was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, and approval of the manuscript.
: All procedures performed in studies involving human participants were in accordance and compliance with the ethical standards of the relevant institutional review boards or independent ethics committees and with the 1964 Helsinki declaration and its later amendments as well as Good Clinical Practice guidelines.
: Informed consent was obtained from all individual participants included in the studies.
: MEG, VB, PH, SJK, and AE-L are employees of Sage Therapeutics, Inc. and own stock or stock options in the company. SM-B reports personal fees from MedScape and grants from Sage Therapeutics, Inc., awarded to the University of Carolina (Chapel Hill, NC, USA) during the conduct of the brexanolone injection clinical trials and grants from Janssen, PCORI, and the NIH outside the submitted work. SA and MF are employees of Acaster Lloyd Consulting, Ltd. and AMF Consulting, respectively, which were paid by Sage Therapeutics to conduct the research reported in this manuscript.